324 related articles for article (PubMed ID: 12187959)
1. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
4. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases.
Korshunov A; Golanov A; Timirgaz V
Acta Neuropathol; 2001 Sep; 102(3):271-7. PubMed ID: 11585252
[TBL] [Abstract][Full Text] [Related]
5. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
6. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
7. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in intracranial ependymomas in children.
Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
[TBL] [Abstract][Full Text] [Related]
9. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Korshunov A; Golanov A
Arch Pathol Lab Med; 2001 Jul; 125(7):892-8. PubMed ID: 11419973
[TBL] [Abstract][Full Text] [Related]
12. Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas.
Nambirajan A; Sharma MC; Gupta RK; Suri V; Singh M; Sarkar C
Neuropathol Appl Neurobiol; 2014 Oct; 40(6):714-25. PubMed ID: 24224478
[TBL] [Abstract][Full Text] [Related]
13. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
Chen C; Chen L; Yao Y; Qin Z; Chen H
J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
[TBL] [Abstract][Full Text] [Related]
14. Nestin expression identifies ependymoma patients with poor outcome.
Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
Korshunov A; Sycheva R; Timirgaz V; Golanov A
J Neurooncol; 1999; 45(3):219-27. PubMed ID: 10845392
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
[TBL] [Abstract][Full Text] [Related]
17. Expression of claudins relates to tumour aggressivity, location and recurrence in ependymomas.
Nordfors K; Haapasalo J; Sallinen PK; Haapasalo H; Soini Y
Histol Histopathol; 2013 Sep; 28(9):1137-46. PubMed ID: 23423606
[TBL] [Abstract][Full Text] [Related]
18. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclo-oxygenase-2 in ependymal tumors.
Roma AA; Prayson RA
Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.
Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W
Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]